The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Dronedarone in High-Risk Permanent Atrial Fibrillation
Open accessAbstract
BACKGROUND: Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. METHODS: We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. RESULTS: After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). CONCLUSIONS: Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,300
Waldo, A. L., Camm, A. J., deRuyter, H., Friedman, P. L., MacNeil, D. J., Pauls, J. F., Pitt, B., Pratt, C. M., Schwartz, P. J., & Veltri, E. P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)02149-6 · Cited by 1,371
Self-citationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,129
Self-citationIncreased Mortality after Dronedarone Therapy for Severe Heart Failure
Køber, L., Torp-Pedersen, C., McMurray, J. J. V., Gøtzsche, O., Lévy, S., Crijns, H., Amlie, J., & Carlsen, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800456 · Cited by 972
Self-citationAssociation of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M. (2003) · JAMA · doi:10.1001/jama.289.7.871 · Cited by 772
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
Singh, B. N., Connolly, S. J., Crijns, H. J. G. M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., & Hohnloser, S. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054686 · Cited by 631
Self-citationAntman, E. M., Wenger, T. L., Butler, V. P., Haber, E., & Smith, T. W. (1990) · Circulation · doi:10.1161/01.cir.81.6.1744 · Cited by 393
Nieuwlaat, R., Prins, M. H., Le Heuzey, J.-Y., Vardas, P. E., Aliot, E., Santini, M., Cobbe, S. M., Widdershoven, J. W. M. G., Baur, L. H., Levy, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn139 · Cited by 287
Self-citationConnolly, S. J., Crijns, H. J. G. M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R. L., & Hohnloser, S. H. (2009) · Circulation · doi:10.1161/circulationaha.109.875252 · Cited by 261
Self-citationChikwe, J., Goldstone, A. B., Passage, J., Anyanwu, A. C., Seeburger, J., Castillo, J. G., Filsoufi, F., Mohr, F. W., & Adams, D. H. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq331 · Cited by 183
Progressive Nature of Paroxysmal Atrial Fibrillation-Observations From a 14-Year Follow-up Study-
Kato, T., Yamashita, T., Sagara, K., Iinuma, H., & Fu, L.-T. (2004) · Circulation Journal · doi:10.1253/circj.68.568 · Cited by 166
Varró, A., Takács, J., Németh, M., Hála, O., Virág, L., Iost, N., Baláti, B., Ágoston, M., Vereckei, A., Pastor, G., et al. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704106 · Cited by 115
Dronedarone in patients with congestive heart failure: insights from ATHENA
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C. T., Connolly, S. J., & for the ATHENA Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq113 · Cited by 75
Self-citationChatelain, P., Meysmans, L., Mattéazzi, J. R., Beaufort, P., & Clinet, M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16397.x · Cited by 70
Page, R. L., Connolly, S. J., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Torp-Pedersen, C. T., & Hohnloser, S. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.028 · Cited by 67
Self-citationLevine, T. B., Giles, T. D., Radzik, D., & Ghali, J. K. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6251-y · Cited by 9
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationJanuary, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Metadata
- Authors
- Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, Á., Blomström, P., Borggrefe, M., Budaj, A., Chen, S.-A., Ching, C. K., Commerford, P., Dans, A., Davy, J.-M., Delacrétaz, E., Di Pasquale, G., Diaz, R., Dorian, P., Flaker, G., Golitsyn, S., Gonzalez-Hermosillo, A., Granger, C. B., Heidbüchel, H., Kautzner, J., Kim, J. S., Lanas, F., Lewis, B. S., Merino, J. L., Morillo, C., Murin, J., Narasimhan, C., Paolasso, E., Parkhomenko, A., Peters, N. S., Sim, K.-H., Stiles, M. K., Tanomsup, S., Toivonen, L., Tomcsányi, J., Torp-Pedersen, C., Tse, H.-F., Vardas, P., Vinereanu, D., Xavier, D., Zhu, J., Zhu, J.-R., Baret-Cormel, L., Weinling, E., Staiger, C., Yusuf, S., Chrolavicius, S., Afzal, R., & Hohnloser, S. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-15
- Volume
- 365
- Issue
- 24
- Pages
- 2268-2276
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121512872
- Cited by
- 544
- References
- 16
- FWCI
- 48.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.